130 related articles for article (PubMed ID: 31366860)
21. Clinical and bacteriological efficacies of sitafloxacin against community-acquired pneumonia caused by Streptococcus pneumoniae: nested cohort within a multicenter clinical trial.
Fujita J; Niki Y; Kadota J; Yanagihara K; Kaku M; Watanabe A; Aoki N; Hori S; Tanigawara Y; Cash HL; Kohno S
J Infect Chemother; 2013 Jun; 19(3):472-9. PubMed ID: 23179958
[TBL] [Abstract][Full Text] [Related]
22. In vitro activity of sitafloxacin against atypical bacteria (2009-2014) and comparison between susceptibility of clinical isolates in 2009 and 2012.
Amano A; Kishi N; Koyama H; Matsuzaki K; Matsumoto S; Uchino K; Yamaguchi H; Yokomizo A; Mizuno M
Jpn J Antibiot; 2016 Sep; 69(3):131-142. PubMed ID: 30226949
[TBL] [Abstract][Full Text] [Related]
23. [In-vitro and in-vivo activities of moxifloxacin and garenoxacin against Mycobacterium leprae].
Gidoh M
Nihon Hansenbyo Gakkai Zasshi; 2007 Feb; 76(1):11-7. PubMed ID: 17315747
[TBL] [Abstract][Full Text] [Related]
24. Risk Factors for Community-Onset Pneumonia Caused by Levofloxacin-Nonsusceptible Streptococcus pneumoniae.
Seok H; Kang CI; Huh K; Cho SY; Ha YE; Chung DR; Peck KR
Microb Drug Resist; 2018 Nov; 24(9):1412-1416. PubMed ID: 29565225
[TBL] [Abstract][Full Text] [Related]
25. Evaluating the antimicrobial efficacy of ceftriaxone regimens: 1 g twice daily versus 2 g once daily in a murine model of
Kato H; Hagihara M; Hiramatsu SI; Suematsu H; Nishiyama N; Asai N; Mikamo H; Yamamoto K; Iwamoto T
JAC Antimicrob Resist; 2024 Jun; 6(3):dlae092. PubMed ID: 38836196
[TBL] [Abstract][Full Text] [Related]
26. In vivo antibacterial activity of chinfloxacin, a new fluoroquinolone antibiotic.
Li GQ; Bai XG; Li CR; Yang XY; Hu XX; Yuan M; Zhang WX; Lou RH; Guo HY; Jiang JD; You XF
J Antimicrob Chemother; 2012 Apr; 67(4):955-61. PubMed ID: 22210757
[TBL] [Abstract][Full Text] [Related]
27. Short-course therapy of gemifloxacin effective against pneumococcal pneumonia in mice.
Bast DJ; Dresser L; Duncan CL; Walker SE; Mandell LA; Low DE; de Azavedo JC
J Chemother; 2006 Dec; 18(6):634-40. PubMed ID: 17267342
[TBL] [Abstract][Full Text] [Related]
28. Comparison of garenoxacin with levofloxacin as antimicrobial prophylaxis in acute myeloid leukemia.
Uni M; Yoshimi A; Yamazaki S; Taoka K; Shinohara A; Nannya Y; Nakamura F; Kurokawa M
Jpn J Clin Oncol; 2015 Aug; 45(8):745-8. PubMed ID: 25989991
[TBL] [Abstract][Full Text] [Related]
29. [Bactericidal activity of sitafloxacin and other new quinolones against antimicrobial resistant Streptococcus pneumoniae].
Kobayashi I; Kanayama A; Hasegawa M; Kaneko A
Jpn J Antibiot; 2013 Feb; 66(1):25-35. PubMed ID: 23777014
[TBL] [Abstract][Full Text] [Related]
30. Pharmacokinetic/Pharmacodynamic Evaluation of a Novel Aminomethylcycline Antibiotic, KBP-7072, in the Neutropenic Murine Pneumonia Model against Staphylococcus aureus and Streptococcus pneumoniae.
Lepak AJ; Zhao M; Liu Q; Wang P; Wang Y; Bader JC; Ambrose PG; Andes DR
Antimicrob Agents Chemother; 2019 Mar; 63(3):. PubMed ID: 30559140
[TBL] [Abstract][Full Text] [Related]
31. Activity of ciprofloxacin and levofloxacin in experimental pneumonia caused by Klebsiella pneumoniae deficient in porins, expressing active efflux and producing QnrA1.
Rodríguez-Martínez JM; Pichardo C; García I; Pachón-Ibañez ME; Docobo-Pérez F; Pascual A; Pachón J; Martínez-Martínez L
Clin Microbiol Infect; 2008 Jul; 14(7):691-7. PubMed ID: 18558942
[TBL] [Abstract][Full Text] [Related]
32. Early switch therapy from intravenous sulbactam/ampicillin to oral garenoxacin in patients with community-acquired pneumonia: a multicenter, randomized study in Japan.
Kohno S; Yanagihara K; Yamamoto Y; Tokimatsu I; Hiramatsu K; Higa F; Tateyama M; Fujita J; Kadota J
J Infect Chemother; 2013 Dec; 19(6):1035-41. PubMed ID: 23695232
[TBL] [Abstract][Full Text] [Related]
33. Pharmacodynamics and bactericidal activity of gatifloxacin in experimental pneumonia caused by penicillin-resistant Streptococcus pneumoniae.
Yanagihara K; Fukuda Y; Miyazaki Y; Tsukamoto K; Hirakata Y; Tomono K; Kadota J; Tashiro T; Murata I; Kohno S
Chemotherapy; 2004 Jun; 50(3):107-12. PubMed ID: 15282438
[TBL] [Abstract][Full Text] [Related]
34. Activity of garenoxacin, an investigational des-F(6)-quinolone, tested against pathogens from community-acquired respiratory tract infections, including those with elevated or resistant-level fluoroquinolone MIC values.
Jones RN; Fritsche TR; Sader HS; Stilwell MG
Diagn Microbiol Infect Dis; 2007 May; 58(1):9-17. PubMed ID: 17408903
[TBL] [Abstract][Full Text] [Related]
35. Comparison of the minimum inhibitory, mutant prevention and minimum bactericidal concentrations of ciprofloxacin, levofloxacin and garenoxacin against enteric Gram-negative urinary tract infection pathogens.
Hansen GT; Blondeau JM
J Chemother; 2005 Oct; 17(5):484-92. PubMed ID: 16323436
[TBL] [Abstract][Full Text] [Related]
36. [Antimicrobial susceptibility surveillance of recent isolates from otorhinolaryngological infections to garenoxacin and other antimicrobial drugs].
Suzuki K; Kurono Y; Kobayashi T; Nishimura T; Baba S; Harabuchi Y; Fujisawa T; Yamanaka N; Ubukata K; Ikeda F
Jpn J Antibiot; 2009 Apr; 62(2):71-8. PubMed ID: 19673349
[TBL] [Abstract][Full Text] [Related]
37. A randomized, double-blind, multicenter Phase II study comparing the efficacy and safety of oral nemonoxacin with oral levofloxacin in the treatment of community-acquired pneumonia.
Liu Y; Zhang Y; Wu J; Zhu D; Sun S; Zhao L; Wang X; Liu H; Ren Z; Wang C; Xiu Q; Xiao Z; Cao Z; Cui S; Yang H; Liang Y; Chen P; Lv Y; Hu C; Lv X; Liu S; Kuang J; Li J; Wang D; Chang L
J Microbiol Immunol Infect; 2017 Dec; 50(6):811-820. PubMed ID: 26748734
[TBL] [Abstract][Full Text] [Related]
38. [In vitro activities of levofloxacin and other antibiotics against fresh clinical isolates].
Matsuzaki K; Koyama H; Chiba A; Omika K; Harada S; Sato Y; Hasegawa M; Kobayashi I; Kaneko A; Sasaki J
Jpn J Antibiot; 1999 Sep; 52(9):571-84. PubMed ID: 10746192
[TBL] [Abstract][Full Text] [Related]
39. [Susceptibility of major pathogens of acute pharyngitis and tonsillitis to levofloxacin and other oral antimicrobial drugs].
Matsuzaki K; Yoshimori K; Shikano M; Watabe E; Sato Y; Hasegawa M; Kobayashi I; Yamanaka N
Jpn J Antibiot; 2003 Jun; 56(3):171-9. PubMed ID: 12942788
[TBL] [Abstract][Full Text] [Related]
40. Mutant selection window of four quinolone antibiotics against clinical isolates of Streptococcus pneumoniae, Haemophilus influenzae and Moraxella catarrhalis.
Nakai H; Sato T; Uno T; Furukawa E; Kawamura M; Takahashi H; Watanabe A; Fujimura S
J Infect Chemother; 2018 Feb; 24(2):83-87. PubMed ID: 29290527
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
